We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Mucosal administration of a live attenuated recombinant COVID-19 vaccine protects nonhuman primates from SARS-CoV-2.
- Authors
Tioni, Mariana F.; Jordan, Robert; Pena, Angie Silva; Garg, Aditya; Wu, Danlu; Phan, Shannon I.; Weiss, Christopher M.; Cheng, Xing; Greenhouse, Jack; Orekov, Tatyana; Valentin, Daniel; Kar, Swagata; Pessaint, Laurent; Andersen, Hanne; Stobart, Christopher C.; Bloodworth, Melissa H.; Stokes Peebles, R.; Liu, Yang; Xie, Xuping; Shi, Pei-Yong
- Abstract
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the causative agent of the COVID-19 global pandemic. SARS-CoV-2 is an enveloped RNA virus that relies on its trimeric surface glycoprotein spike for entry into host cells. Here we describe the COVID-19 vaccine candidate MV-014-212, a live, attenuated, recombinant human respiratory syncytial virus expressing a chimeric SARS-CoV-2 spike as the only viral envelope protein. MV-014-212 was attenuated and immunogenic in African green monkeys (AGMs). One mucosal administration of MV-014-212 in AGMs protected against SARS-CoV-2 challenge, reducing by more than 200-fold the peak shedding of SARS-CoV-2 in the nose. MV-014-212 elicited mucosal immunoglobulin A in the nose and neutralizing antibodies in serum that exhibited cross-neutralization against virus variants of concern Alpha, Beta, and Delta. Intranasally delivered, live attenuated vaccines such as MV-014-212 entail low-cost manufacturing suitable for global deployment. MV-014-212 is currently in Phase 1 clinical trials as an intranasal COVID-19 vaccine.
- Subjects
SARS-CoV-2; CHIMERIC proteins; COVID-19 vaccines; IMMUNOGLOBULINS; RESPIRATORY syncytial virus; COVID-19 pandemic; IMMUNOGLOBULIN A; VIRAL envelope proteins
- Publication
NPJ Vaccines, 2022, Vol 7, Issue 1, p1
- ISSN
2059-0105
- Publication type
Article
- DOI
10.1038/s41541-022-00509-6